These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31515627)

  • 41. Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations.
    Tauziède-Espariat A; Saffroy R; Pagès M; Pallud J; Legrand L; Besnard A; Lacombe J; Lot G; Borha A; Tazi S; Adle-Biassette H; Polivka M; Lechapt E; Varlet P
    Clin Neuropathol; 2018; 37(5):209-216. PubMed ID: 29809131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histone H3 mutations in pediatric brain tumors.
    Liu X; McEachron TA; Schwartzentruber J; Wu G
    Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a018689. PubMed ID: 24691963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
    Nazem A; Lavezo J; Abdullaev Z; Aldape K; Quezado M; Cimino PJ; Pratt DW; Jenkins RB; Ida CM
    J Neuropathol Exp Neurol; 2023 Dec; 83(1):58-60. PubMed ID: 37878797
    [No Abstract]   [Full Text] [Related]  

  • 44. Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
    Wood MD; Neff T; Nickerson JP; Sayama C; Raslan AM; Ambady P; Corless CL; Nazemi KJ
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):460-463. PubMed ID: 33296093
    [No Abstract]   [Full Text] [Related]  

  • 45. TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas.
    Chan AK; Mao Y; Ng HK
    N Engl J Med; 2016 Dec; 375(22):2206-2208. PubMed ID: 27959765
    [No Abstract]   [Full Text] [Related]  

  • 46. [H3K27 positive diffuse midline glioma. Report of one case].
    Araneda P; Sujima E; Paredes-Manzo P; Vallejo R; Valdivia F; Sinning M; Gallegos M; Fuller G
    Rev Med Chil; 2019 Nov; 147(11):1487-1490. PubMed ID: 32186609
    [No Abstract]   [Full Text] [Related]  

  • 47. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A rare presentation of a spinal diffuse midline glioma in a child: a case report.
    Isfaoun Z; Laasri K; Jidal M; Cherradi N; Melhaoui A; Chat L; Haddad SE; Kababri ME; Khorassani ME; Kili A; Ansari NE; Hessissen L
    Pan Afr Med J; 2023; 44():183. PubMed ID: 37484594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours.
    Nguyen AT; Colin C; Nanni-Metellus I; Padovani L; Maurage CA; Varlet P; Miquel C; Uro-Coste E; Godfraind C; Lechapt-Zalcman E; Labrousse F; Gauchotte G; Silva K; Jouvet A; Figarella-Branger D;
    Neuropathol Appl Neurobiol; 2015 Apr; 41(3):403-8. PubMed ID: 25389051
    [No Abstract]   [Full Text] [Related]  

  • 50. Malignant gliomas with H3F3A G34R mutation or MYCN amplification in pediatric patients with Li Fraumeni syndrome.
    Schoof M; Kordes U; Volk AE; Al-Kershi S; Kresbach C; Schüller U
    Acta Neuropathol; 2021 Sep; 142(3):591-593. PubMed ID: 34264394
    [No Abstract]   [Full Text] [Related]  

  • 51. Biopsying a spinal cord lesion: A diagnostic dilemma. Case report and review of literature.
    Dormegny L; Chibbaro S; Ganau M; Santin M; Kremer L; Proust F
    Neurochirurgie; 2018 Dec; 64(6):425-430. PubMed ID: 30243464
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoplastic Myelopathies.
    Wu J; Ranjan S
    Continuum (Minneap Minn); 2018 Apr; 24(2, Spinal Cord Disorders):474-496. PubMed ID: 29613896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
    Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
    World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
    Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
    J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas.
    Ellis JA; Canoll P; McCormick PC; Feldstein NA; Anderson RC; Angevine PD; Kaiser MG; McCormick PC; Bruce JN; Ogden AT
    J Neurooncol; 2012 Jan; 106(2):235-42. PubMed ID: 21789698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytogenetic studies of pediatric brain and spinal cord tumors.
    Chadduck WM; Boop FA; Sawyer JR
    Pediatr Neurosurg; 1991-1992; 17(2):57-65. PubMed ID: 1815730
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histone H3 mutations--a special role for H3.3 in tumorigenesis?
    Kallappagoudar S; Yadav RK; Lowe BR; Partridge JF
    Chromosoma; 2015 Jun; 124(2):177-89. PubMed ID: 25773741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.